EFFECT OF ADJUVANTS ON IMMUNOGENICITY OF MN RECOMBINANT GLYCOPROTEIN-120 IN GUINEA-PIGS
EFFECT OF ADJUVANTS ON IMMUNOGENICITY OF MN RECOMBINANT GLYCOPROTEIN-120 IN GUINEA-PIGS
复制标题
DOI：
10.1089/aid.1995.11.203
复制
发表时间：
1995-02-01
影响因子：
1.5
通讯作者：
BERMAN, PW
中科院分区：
文献类型：
--
作者：
POWELL, MF;EASTMAN, DJ;BERMAN, PW
使用具有不同物理和化学特性的佐剂制剂，在豚鼠中评估了来自 HIV-1 MN 株（一种候选 HIV-1 疫苗）的重组 gp120 的免疫原性。测试的佐剂包括弗氏佐剂(FA)、明矾和新型佐剂QS-21。这些研究表明，与其他两种测试的佐剂相比，QS-21 具有许多优势。 QS-21 制剂加速了 MN rgp120 抗体的产生，并在单次免疫后引发完全血清转化。 QS-21 将抗体生产的抗原剂量反应曲线改变了三个数量级，从而能够更经济地使用抗原。接受 QS-21: 制剂的动物中针对 MN rgp120 和针对 V3 结构域中主要中和决定簇的抗体滴度高于用其他佐剂免疫的动物，并且与体外测定中较高的病毒中和滴度良好相关。这些结果支持在未来候选 HIV-1 疫苗的临床试验中对 QS-21 进行测试。
The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21:formulations than in animals immunized with the other adjuvants, and correlated well with higher;virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.